

measuring a first amount of one or more soluble A β (x- ≥ 41) peptides in the CSF of a non-human animal [used as a model of Alzheimer's disease] model that exhibits cerebral deposition of A β ;

administering the compound to the non-human animal model;

measuring a second amount of said one or more soluble A β (x- ≥ 41) peptides in the CSF of the non-human animal model; and comparing the first amount with the second amount, the difference indicating whether the compound increases, decreases, or leaves unchanged the amount of soluble A β (x- ≥ 41) in the CSF.

43. (Once amended) The method of claim 42 wherein the non-human animal model is a rodent model.

44. (Once amended) The method of claim 43 wherein the rodent model is a mouse model.

45. (Once amended) The method of claim 42 wherein the non-human animal model is a transgenic animal model having an expression cassette that drives expression of a sequence which encodes the Swedish mutation of an APP gene.

46. (Once amended) The method of claim 45 wherein the non-human animal model is a rodent model.

47. (Once amended) The method of claim 46 wherein the rodent model is a mouse model.

REMARKS

I. STATUS OF THE CLAIMS

Claims 42-47 were examined and stand rejected. Applicants have amended all the claims. Therefore, claims 42-47 are presented for examination.